Summary
There have been many attempts to discover neuroprotective drugs for the treatment of Parkinson’s disease (PD). Many ofthese compounds either do not cross the blood brain barrier or are not very effective in the 6-hydroxydopamine or MPTP (N-methyl-4-phenyl-1,2,3,6-terahydropyridine) models of PD. We have examined several compounds including dopamine receptor agonist bromocritine, lisuride, pergolide and R-apomorphine for their neuroprotective action against the above neurotoxins in PC12 and dopamine neuroblastoma cell lines in culture and in vivo. R-apomorphine exhibited relatively potent neuroprotective action in vitro, cell culture and in vivo as a radical scavenger and iron chelator, because of its catechol structure. The recent clinical trials with apomorphine, where parkinsonian subjects can be weaned off L-dopa would suggest that this drug either exerts a neuroprotective action or that continuous sustained stimulation of dopamine receptor may be responsible for its unusual pharmacological activity. Apomorphine has a far more broad neuroprotective activity in the various models as compared with 1-selegiline and may therefore be an ideal drug to study neuroprotection in parkinsonian subjects with the use of PET or SPECT.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Andrew R, Watson D.G., Best S.A., Midgley J.M., Wenlong H, Petty R.K. (1993) The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem Res 18: 1175–1177
Ben Shachar D, Eshel G, Finberg J.P., You dim M.B. (1991a) The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 56: 1441–1444
Ben Shachar D, Riederer P, Youdim M.B. (1991b) Iron-melanin interaction and lipid peroxidation: implications for Parkinson’s disease. J Neurochem 57: 1609–1614
Ben Shachar D, Zuk R, Glinka Y (1995) Dopamine neurotoxicity: inhibition of mitochondrial respiration. J Neurochem 64: 718–723
Dexter D.T., Jenner P, Schapira A.H., Marsden C.D. (1992) Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson’s Disease Research Group. Ann Neurol 32 [Suppl]: S94-100
Esterbauer H (1980) Aldehydes of lipid peroxidation. In: McBrien DCH, Slater TF (eds) Free radicals, peroxidation, and cancer. Academic Press, London, pp 101–122
Glinka Y, Gasswen M, Youdim M.B.H. (1997) Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm 50 [Suppl]: 55–66
Gancher S.T., Nutt J.G., Woodward W.R. (1995) Apomorphine infusional therapy in Parkinson’s disease: clinical utility and lack of tolerance. Mov Disord 10: 37–43
Gassen M, Glinka Y, Pinchasi B, You dim M.B. (1996) Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol 308: 219–225
Gassen M, Gorss A, You dim M.B.H. (1998) Apomorphine enantiomers protect pheochromocytma (PC12) cells from oxidative stress induced by hydrogen peroxide and 6-hydroxydopamine. Mov Disord 13: 242–248
Gerlach M, Ben Shachar D, Riederer P, Youdim M.B. (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63: 793–807
Glinka Y, Tipton K.F., You dim M.B. (1996) Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine. J Neurochem 66: 2004–2010
Grünblatt E, Mandel S, Berkuzki T, You dim M.B.H. (1999) Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov Disord 14: 612–618
Jellinger K, Linert L, Kienzl E, Herlinger E, Youdim M.B., Ben Shachar D, Riederer P (1991) Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson’s disease Iron-melanin interaction and lipid peroxidation: implications for Parkinson’s disease. J Neural Transm 57 [Suppl]: 1609–1614
Lees A.J. (1993) Dopamine agonists in Parkinson’s disease: a look at apomorphine. Fundam Clin Pharmacol 7: 121–128
Linert W, Herlinger E, Jameson R.F., Keizl E, Jellinger K, You dim M.B.H. (1996) Dopamine, 6-hydroxydopamine, iron and dioxygen, their mutal interaction and possible implications in the development of Parkinson’s disease. Biochim Biophyys Acta 131: 160–168
Liu J, Mori A (1993) Monoamine metabolism provides an antioxidant defense in the brain against oxidant- and free radical-induced damage. Arch Biochem Biophys 302:118–127
Monteiro H.P., Winterbourn C.C., Mytilineou C, Danias P (1989) 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation 6-Hydroxydopamine toxicity to dopamine neurons in culture: potentiation by the addition of superoxide dismutase and N-acetylcysteine. Biochem Pharmacol 38: 1872–1875
Riederer P, Sofie E, Rausch W.D., Jellinger K, Youdim M.B.H. (1989) Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains. J Neurochem 52: 515–520
Riederer P, Dirr A, Goetz M, Sofie E, Jellinger K, Youdim M.B. (1992) Distribution of iron in different brain regions and subcellular compartments in Parkinson’s disease. Ann Neurol 32 [Suppl]: S101–104
Shoham S, Glinka Y, Tenne Z, Youdim M.B.H. (1996) Brain iron: function and dysfunction in relation to cognitive processes. In: Hallberg L, Asp NG (eds) Iron nutrition in health and disease. John Libbey, London, pp 205–218
Sofie E, Paulus W, Jellinger K, Riederer P, Youdim M.B. (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 56: 978–982
Stadtman E.R. (1993) Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Annu Rev Biochem 62: 797–821
Vimard F, Nouvelot A, Duval D (1996) Cytotoxic effects of an oxidative stress on neuronal-like pheochromocytoma cells (PCI2). Biochem Pharmacol 51: 1389–1395
Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman E.R., Mizuno Y (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 93: 2696–2701
Youdim M.B.H. (1990) Neuropharmacological and neurochemical aspects of iron deficiency. In: Dobbing J (ed) Brain, behaviour and iron in the infant brain. Springer, Berlin Heidelberg New York Tekyo, pp 83–132
Youdim M.B.H., Riederer P (1997) Understanding Parkinson’s disease. Sci Am 267: 52–59
Youdim M.B.H., Ben-Shachar D, Riederer P (1993a) Iron-melanin interaction and Parkinson’s disease. NIPS 8: 45–49
Youdim M.B.H., Ben-Shachar D, Riederer P (1993b) The possible role of iron in the etiopathology of Parkinson’s disease. Mov Disord 8: 1–12
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Wien
About this paper
Cite this paper
Youdim, M.B.H., Gassen, M., Gross, A., Mandel, S., Grünblatt, E. (2000). Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine. In: Mizuno, Y., Calne, D.B., Horowski, R., Poewe, W., Riederer, P., Youdim, M.B.H. (eds) Advances in Research on Neurodegeneration. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6284-2_7
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6284-2_7
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-7246-9
Online ISBN: 978-3-7091-6284-2
eBook Packages: Springer Book Archive